Empirical therapy advisor
Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.
Based on 107 first isolates · ICU · Skin / wound infection · 2023-12-17 → 2024-12-15
Intensive care unitNo single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
meropenem 50 % (40 %–59 %)
Best two-drug combination: vancomycin + meropenem covers 99 % (95 %–100 %)
Take cultures before treatment; consider a combination and discuss with infectious
diseases if the patient is severely ill.
Not covered: Staphylococcus aureus (38 %), Enterococcus faecalis (11 %), Pseudomonas aeruginosa (1 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
mecillinam MEC
not for this site0 %
0 %
n = 5
trimethoprim TMP
not for this site0 %
0 %
n = 5
nitrofurantoin NIT
not for this site0 %
0 %
n = 5
Most likely organisms for this profile
Staphylococcus aureus
38 %
Pseudomonas aeruginosa
15 %
Escherichia coli
12 %
Enterococcus faecalis
11 %
Proteus mirabilis
10 %
Citrobacter freundii
7 %
Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.